Gary Frashier

Mr. Frashier served as Chief ExecuOve Officer and Chairman of OSI PharmaceuOcals, and it was during his tenure at OSI that the leading generic-based cancer drug, “Tarceva” was discovered and developed thru initial human Proof of Concept clinical trials. Tarceva is now sold by Roche and Genentech and has annual sales of over $1.7 billion with continuing expansion into new cancer areas. Astellas Pharma acquired OSI in 2010 for $4 billion. Mr. Frashier has raised over $250 million from a combination of equity financings and other sources has organized many collaborations and joint programs with major pharmaceutical companies and has served as a founder of several life science companies. Prior to OSI, Mr. Frashier served as President, Internacional, and ExecuOve Vice President of Millipore CorporaOon; President and CEO of Waters CorporaOon, the leader in liquid chromatography; and CEO of Genex CorporaOon, a protein engineering company. He has participated as a founder in organizing several biotechnology companies, including Merrimack PharmaceuOcals, Inc.; Eutropics, Inc.; Targazyme and Apex BioVentures AcquisiOon CorporaOon. He currently serves on the Board of Directors of Achillion PharmaceuOcals, Inc. (NASDAQ), ViroXis CorporaOon, Inc., and Metric Medical Devices, Inc., and he is an Advisor to Santalis CorporaOon and StemBioSys. He is a Strategic Partner in SV Life Sciences LP, a major venture capital company. He has served on numerous other private and public life science company Boards, including Maxim PharmaceuOcals, Tekmira PharmaceuOcals (Canada), Apex BioVentures AcquisiOon CorporaOon, Tanox, Inc., Cytoclonal PharmaceuOcals, Exegenics PharmaceuOcals, Aderis Pharmaceuticals, and Alseres Pharmaceuticals. Mr. Frashier has a B.S. in Chemical Engineering from Texas Tech University, which has designated him a “DisOnguished Engineer Graduate,” and an M.B.A. from the Massachusetts Institute of Technology, where he was selected as an “Alfred P. Sloan Fellow.” He is a registered Professional Engineer in Chemical Engineering in Texas.